Gregory R. Naumiec
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Associate Professor
Also affiliated: National Institutes of Health (2014–2017); University of Rhode Island (2008–2015); Conway School of Landscape Design (2018–2020); Kingston University (2008); National Institute of Mental Health (2014–2017)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Gregory R. Naumiec's research focuses on the synthesis and evaluation of novel compounds for therapeutic applications. His work has explored disquaramide compounds as potential anti-leishmanial drugs, as indicated by his 2024 publication. Naumiec's scholarly output includes 12 publications with 223 citations and an h-index of 6. He has collaborated with researchers from the University of Arkansas for Medical Sciences, including Karl W. Boehme, Tiffany Weinkopff, and Alexx Weaver, as well as Gabriel Gifford from the University of Central Arkansas. His research interests align with several key areas within medical science, particularly concerning molecular targets and drug development.
Metrics
- h-index: 6
- Publications: 12
- Citations: 224
Selected Publications
-
Aqueous Synthesis of Monosquaramides (2026)
-
Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs (2024)
-
<i>T</i><sub>1</sub> Measurement by NMR Inversion Recovery: An Upper-Division Undergraduate Experiment in Advanced NMR Techniques Demonstrating the Concept of Contrast-Enhanced MRI (2020)
-
Improved Synthesis of 2-Trifluoromethyl-10-aminopropylphenothiazine: Making 2-Trifluoromethyl-10-aminopropylphenothiazine Readily Available for Calmodulin Purification (2018)
Collaboration Network
Top Collaborators
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Similar Researchers
Based on overlapping research topics